Stability of antineoplastic agents in use for home-based intravenous chemotherapy
- 644 Downloads
Aim of the review The aim of this work was first to define which antineoplastic agents with sufficiently long stability could be eligible in the circuit of home-based therapy (centralised preparation, transport to the patient’s home and administration by nurses) and, second, to propose a standardisation of the stability data of anticancer drugs in use for home hospitalisation. Method A survey carried out in six hospital pharmacies of the Assistance Publique—Hôpitaux de Paris (AP-HP) hospitals, with important activity in oncology, listed the stability data used locally by each site. The final goal is to reach a consensus for the stability of cytotoxic drugs, which was the result of an original collaboration between the pharmacists of the compounding unit and the quality control unit. These results were compared to marketing authorisation data. Results The survey showed that eight antineoplastic agents of 34 were prepared under identical conditions (infusion diluent, concentration range, protection from light, temperature) by all hospitals (3 ≤ n ≤ 6): the stability was identical between each site for only two cytotoxic drug preparations (fotemustine and gemcitabine) and varied by up to 168 h or 7 days for the preparations of dacarbazine, epirubicine and cisplatin. Stability validated by pharmacists and those provided by marketing authorisation ranged respectively from “extemporaneously prepared” at 1,344 h (median = 168 h) to “extemporaneously prepared” at 720 h (median = 4 h). For 11 antineoplastic drugs, no information about the stability after compounding was specified in the marketing authorisation. Of all cytotoxic drugs used in the Hospital at Home of AP-HP, stability after compounding validated by pharmacists was less than 30 h for six of them, between 30 and 78 h for four and exceeding 78 h for the remaining 24. Conclusion Considering the lack of data about cytotoxic drugs stability provided by the pharmaceutical companies and the difficulties in retrieving and interpreting the literature data, a consensus on the stability of cytotoxic drug preparations is essential for the current practice. With this approach, initiated for home hospitalisation, we propose in this study an initiative of the standardisation of stability data which offers a decision support for other centres.
KeywordsAntineoplastic agents Centralised preparation units Decision support Home-based chemotherapy Pharmaceutical manufacturers Stability Standardisation
We would like to acknowledge the working group of hospital pharmacists for their involvement in this work: Louis Joyeux (Hospital at Home, AP-HP, Paris), Nathalie Leguyader (Armand Trousseau, AP-HP, Paris), Isabelle Madelaine-Chambrin (Saint Louis, AP-HP, Paris), Nicole Poisson (AGEPS, AP-HP, Paris), Delphine Pozzi (Raymond Poincaré, AP-HP, Garches), Patrice Prognon (HEGP, AP-HP, Paris), Marie Savet (Robert Debré, AP-HP, Paris).
Conflicts of interest
The authors declare no conflicts of interest directly relevant to the content of this manuscript.
No funding was received.
- 1.Borras JM, Sanchez-Hernandez A, Navarro M, Martinez M, Mendez E, Ponton JLL, et al. Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial. BMJ. 2001;322(7290):826. doi: 10.1136/bmj.322.7290.826.PubMedCrossRefGoogle Scholar
- 7.The French National Cancer Institute. Plan cancer 2003–2007. Mission interministérielle pour la lutte contre le cancer. Available online at: https://www.e-cancer.fr/v1/fichiers/public/3_brochure_plan_cancer.pdf.
- 8.Circulaire interministérielle DHOS/SDO/2005/101 du 22 février 2005 relative à l’organisation des soins en cancérologie NOR: SANH0530076C. Available online at: http://www.sante.gouv.fr/htm/dossiers/cancer/circ101.pdf.
- 9.Haute Autorité de Santé. Practice guidelines: patient selection criteria for at-home cancer chemotherapy—formal consensus. September 2003. Available online at: http://www.has-sante.fr/portail/upload/docs/application/pdf/at_home_chemotherapy_guidelines_2006_11_20__12_27_55_544.pdf.
- 11.American Society of Health-System Pharmacy. ASHP guidelines on handling hazardous drugs. Am J Health Syst Pharm. 2006;(63):1172–91. Available online at: http://www.ajhp.org/cgi/content/full/63/12/1172.
- 12.Agence Française de Sécurité Sanitaire des Produits de Santé. Bonnes pratiques de préparation. 3 Décembre 2007. Available online at: http://afssaps.sante.fr/pdf/5/bonne-pratique-preparation.pdf.
- 13.National Institute for Occupational Safety and Health. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings. NIOSH Publication September 2004;165. Available online at: http://www.cdc.gov/niosh/docs/2004-165/.
- 19.Walker SE, Milliken D, Law S. Stability of bortezomib reconstituted with 0.9% sodium chloride at 4°C and room temperature (23°C). CJHP. 2008;61(1):14–20.Google Scholar
- 22.Rondelot G, Serrurier C, Vigneron J, Zenier H, May I, Demoré B. Stability of pemetrexed 25 mg/mL in a glass vial and 5 mg/mL stored in a PVC container after storage for one month at 2–8°C. EJHP Sci. 2007;13(1):14–6.Google Scholar
- 24.Dine T, Lebegue S, Benaji B, Gressier B, Segard V, Goudaliez F, et al. Stability and compatibility studies of four cytostatic agents (fluorouracil, dacarbazine, cyclophosphamide and ifosfamide) with PVC infusion bags. Pharm Sci Commun. 1994;4:97–101.Google Scholar
- 25.Vigneron J. Stability studies of drugs used in oncology: the role of the hospital pharmacist. EJHP Pract. 2006;12(6):75–6.Google Scholar
- 30.Daouphars M, Vigneron J, Perrin A, Hoffman MA. Stability of cladribine in either polyethylene containers or polyvinyl chloride bags. EJHP Sci. 1997;3(4):154–6.Google Scholar
- 35.Zhang Y, Trissel LA. Physical and chemical stability of etoposide phosphate solutions. J Am Pharm Assoc (Wash). 1999;39(2):146–50.Google Scholar
- 36.Biondi L, Nairn JG. Stability of 5-fluorouracil and flucytosine in parenteral solutions. CJHP. 1986;39(3):60–4.Google Scholar
- 38.Dine T, Khalfi F, Gressier B, Luyckx M, Brunet C, Ballester L, et al. Stability study of fotemustine in PVC infusion bags and sets under various conditions using a stability-indicating high-performance liquid chromatographic assay. J Pharm Biomed Anal. 1998;18(3):373–81. doi: 10.1016/S0731-7085(98)00096-X.PubMedCrossRefGoogle Scholar
- 39.Xu Q, Zhang Y, Trissel LA. Physical and chemical stability of gemcitabine hydrochloride solutions. J Am Pharm Assoc (Wash). 1999;39(4):509–13.Google Scholar
- 41.Lecompte D, Bousselet M, Magnam J. Stability of mitoxantrone (Novantrone®) after dilution in PVC infusions. J Pharm Clin. 1990;9:159–65.Google Scholar
- 46.Krämer I, Thiesen J. Stability of topotecan infusion solutions in polyvinylchloride bags and elastomeric portable infusion devices. J Oncol Pharm Pract. 1999;5(2):75–82.Google Scholar